Did you know?

ChinaBio® Group is a consulting and advisory firm helping life science companies and investors achieve success in China. ChinaBio works with U.S., European and APAC companies and investors seeking partnerships, acquisitions, novel technologies and funding in China.  

Learn more >>

Free Newsletter

Have the latest stories on China's life science industry delivered to your inbox daily or weekly - free!

See preview >>

  Email address:
   

Symic Raises $30 Million for Matrix Biology Program; Looks for China Partners

publication date: May 24, 2017
Symic Bio, a Bay-area matrix biology company, announced a $30 million B financing that included two prominent China-focused investors: HEDA Ventures and Ally Bridge Group. Symic CEO Ken Horne expects these investors will help Symic form China partnerships, according to BioCentury. Symic focuses on therapeutics for the sponge-like extracellular matrix in the body that provides an environment in which cells develop. The company has two drug candidates in clinical development. More details....

Share this with colleagues:  


This article is available for purchase - please click here for details.

Sorry this page is available to subscribers only.
If you're not a subscriber why not subscribe today?

If you are already a subscriber, please login.

If you believe you should have received this message in error, please contact us.


 

To gain access to the members only content click here to subscribe.

You will be given immediate access to premium content on the site.

ChinaBio® News

Greg Scott BIO-Europe Interview
Greg Scott Interviewed at BIO-Europe Spring

How to bring your China assets to China in 8 minutes

Greg Scott Mendelspod Interview
"Mr. Bio in China."
Mendelspod Interview

Multinational pharma held to a higher standard in China

Partner Event
November 2-3, 2023 | Shanghai
November 7-8, 2023 | Digital